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Purpose

Outcomes in patients with atrial fibrillation who develop acute mesenteric ischemia, and the impact of
anticoagulation on complications, are not defined.

Methods	Patients admitted with acute mesenteric ischemia in the National Inpatient Sample from 2007, with and
without atrial fibrillation, were compared for in-hospital outcomes using multivariate regression, and the
impact of prior anticoagulation determined.
Results

Of 48,872 patients with acute mesenteric ischemia, 8,306 had atrial fibrillation, with 680 patients also on
anticoagulation. Atrial fibrillation patients were more likely to be older and have hypertension, heart failure,
or chronic lung or renal disease. After adjusting for potential confounders, atrial fibrillation remained
independently associated with higher mortality (P<0.001). Patients on anticoagulation were less likely
to have intestinal resections or shock, less likely to need intubation and had lesser hospital stay and
hospital charges compared to those not on anticoagulation.

Conclusions

In patients with acute mesenteric ischemia, presence of atrial fibrillation increases mortality, but prior
anticoagulation reduces incidence of complications, length of stay and hospital charges. (J Patient Cent
Res Rev. 2016;3:177-186.)
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Atrial fibrillation (AF) is the most common cardiac
arrhythmia, affecting about 5 million patients in the
United States.1-3 It is characterized by disorganized
atrial electrical activation causing an irregular heart
rate and loss of atrial contractility.4 In the presence
of risk factors, this increases susceptibility for
thromboembolic events that can cause ischemic
stroke and/or systemic arterial occlusion.5 Embolic
obstruction of the superior mesenteric artery or its
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branches results in acute mesenteric ischemia (AMsI),
which can lead to intestinal necrosis, peritonitis and
death if left untreated.5 The emboli originate from the
heart in more than 75% of cases and preferentially
lodge distal to the origin of the middle colic artery
from the superior mesenteric artery.5
AF is a risk factor for AMsI, with a reported annual
incidence of 0.14% in patients with AF and a
mortality rate of about 70%.6 Early diagnosis and
prompt surgical intervention are essential to improve
survival, and any delay in diagnosis is associated
with poor outcomes.7,8 Despite advancements in
management –– including endovascular stenting
of the mesenteric arterial lesion, thrombolysis of
fresh thrombus and exploratory laparotomy with
embolectomy followed by resection of necrotic bowel
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–– the survival rate remains poor and reflects the low
percentage of diagnoses made before the development
of intestinal necrosis.9,10 A significant reduction in the
incidence of ischemic stroke in patients with AF has
been demonstrated by anticoagulation.11-15 However,
such information is not available for those with AMsI,
and the effect of prior anticoagulation on outcomes of
AMsI in patients with AF is not known.
In addition to identifying independent predictors of
AMsI, we investigated the differences in outcomes
of AMsI patients with and without AF as well as the
impact of prior anticoagulation on these outcomes.

METHODS

Data Source and Objectives
Data were obtained from the National Inpatient
Sample (NIS) database for the year 2007. The NIS
is sponsored by the Agency for Healthcare Research
and Quality as a part of the Healthcare Cost and
Utilization Project and is the largest publicly
available all-payer database in the United States.
The database contains discharge-level data from
about 1,000 hospitals designed to approximate a
20% stratified sample of all community hospitals
in the United States. Currently, 46 states contribute
data to NIS. The database contains more than 100
clinical and nonclinical elements for each hospital
stay, including primary and secondary diagnoses and
procedures, admission and discharge status, patient
demographics, hospital characteristics, payer source,
comorbidity measures and length of stay.16 Discharge
weights are provided in each patient discharge
record and then used to obtain national estimates. As
the data are based on an administrative dataset and
de-identified, no informed consent or institutional
review board approval was applicable to this study.
Our objectives were to determine independent risk
factors for AMsI, whether there was a difference in
outcome between patients developing AMsI with or
without AF, and if being on anticoagulation had an
effect on the outcomes of patients with AMsI in the
setting of AF.
Study Population and Outcomes
We used the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) code
557.0 to identify all patients with a diagnosis of AMsI
(n=48,872) and code 427.31 for AF (n=3,325,324).
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Of the patients with AMsI, 8,306 had a concomitant
diagnosis of AF while 40,566 had no AF. Within the
AF plus AMsI group, those on anticoagulation were
identified using the ICD-9-CM code V5861 (n=680);
the remaining patients (n=7,626) were considered to be
not on anticoagulation (Figure 1).
Primary outcome of interest was in-hospital mortality.
Secondary outcomes of interest were length of stay
longer than 14 days (75% quartile), nonroutine
discharges (discharge dispositions other than home
or self-care), total hospital charges, endotracheal
intubation/mechanical ventilation (ICD-9-CM codes
96.04, 96.70–96.72), small bowel resection (codes
45.61–45.63), colon resection (codes 45.71–45.79,
45.81–45.83), total parenteral nutrition (code 99.15)
and shock (codes 785.50–785.52, 785.59, 998.09).

Figure 1. Patients with acute mesenteric ischemia
in National Inpatient Sample from 2007. Flowchart
depicting selection of the study population and number
of patients with acute mesenteric ischemia in those with
or without history of atrial fibrillation and anticoagulation.

Statistical Analysis
Multivariable logistic regression was used with
AMsI as a binary dependent variable and baseline
patient characteristics –– including demographics
(age, gender, race), primary expected payer, median
household income by patient ZIP code, 29 Elixhauser
comorbidities (as defined by the Agency for Healthcare
Research and Quality)17,18 and other clinically relevant
comorbidities (dyslipidemia, hypertension, congestive
heart failure, chronic lung disease, coagulation
disorders, diabetes mellitus, liver disorders,
neurological disorders, obesity, perivascular disease,
Original Research

renal failure, tumor, tumor with metastasis, valvular
heart disease) –– as independent covariates.19 A list
of ICD-9-CM and Clinical Classifications Software
codes used to identify comorbidities is provided online
in Supplemental Appendix 1.
Data were analyzed using SAS statistical software
package Version 9.4 (SAS Institute Inc., Cary, NC).
Continuous variables were summarized using means
with 95% confidence intervals (CI). Similarly,
categorical variables were summarized with the use
of frequencies and percentages. Chi-squared test was
used to compare categorical variables and the t-test
to compare continuous variables. Appropriate survey
discharge weights were applied for NIS data, and survey
procedure commands were applied for the analysis. A
two-sided P-value < 0.05 was used to assess statistical
significance. Multivariate logistic regression was used
to compare outcomes between the AF versus no AF
groups and the AF on anticoagulation versus AF not on
anticoagulation groups. The regression model adjusted
for demographics, primary expected payer, median
household income, all Elixhauser comorbidities, other
clinically relevant comorbidities, primary diagnosis of
AF and secondary diagnosis of AMsI.

CI: 1.27–1.43, P<0.001), white race (OR: 1.73, 95%
CI: 1.53–1.96, P<0.001), emergency admission type
(OR: 1.64, 95% CI: 1.42–1.89, P<0.001), peripheral
vascular disease (OR: 2.11, 95% CI: 1.93–2.31,
P<0.001), chronic blood loss anemia (OR: 1.80, 95%
CI: 1.59–2.05, P<0.001), heart failure (OR: 1.31, 95%
CI: 1.21–1.41, P<0.001), liver disorders (OR: 1.39,
95% CI: 1.21–1.59, P<0.001), valvular heart disease
(OR: 1.24, 95% CI: 1.13–1.37, P<0.001) and renal
failure (OR: 1.10, 95% CI: 1.01–1.19, P=0.03) were
associated with an increased risk of AMsI (Table 2).
A history of anticoagulation use, hyperlipidemia,
hypertension, tobacco use, diabetes mellitus, obesity
or neurological disorder was associated with a lower
risk for AMsI.

Baseline characteristics of patients diagnosed with
AMsI in 2007 are described in Table 1. In general,
patients with AMsI and AF were more likely to be
older in age, white and nonsmokers. They also were
more likely to have heart failure, chronic lung disease,
peripheral vascular disease, renal failure and valvular
heart disease (P<0.001).

Influence of AF on Outcomes in Patients
With AMsI
Patients with AMsI and history of AF were more likely
to have adverse outcomes compared to patients with no
history of AF (Table 3). A significantly higher percentage
of patients with AF and AMsI required colectomy (24%
vs 18%, P<0.001) or total parenteral nutrition (17% vs
11%, P<0.001) compared to those without history of AF.
There was a statistically significant greater likelihood
of shock, intubation or mechanical ventilation as well
as greater in-hospital mortality, hospital charges, length
of stay and nonroutine discharges (surrogate marker
for severity of disease). The unadjusted OR of dying
in AF versus non-AF was 2.33 (95% CI: 2.06–2.63).
On multivariate logistic regression with adjustment
for different confounders, including the comorbidities,
the OR of dying still remained significant at 1.59 with
95% CI of 1.3–1.9 (P<0.001).

Predictors for AMsI
Patients with AF had significantly higher odds of
developing AMsI compared to patients without
AF (odds ratio [OR]: 1.16, 95% CI: 1.08–1.25,
P<0.001). The odds of developing AMsI increased
with age. Patients 50 to 74 years of age were at the
highest risk (OR: 4.55, 95% CI: 3.88–5.34, P<0.001)
of developing AMsI. Further analysis to assess the
difference in AMsI risk between elderly (65–74 years)
and middle-aged patients (50–64 years) demonstrated
a statistically significant greater risk of AMsI in
the older patients (OR: 1.24, 95% CI: 1.12–1.36,
P<0.001). In addition, female sex (OR: 1.35, 95%

Effect of Anticoagulation on Outcomes of AF
Patients With AMsI
A lower odds ratio was observed for AMsI in younger
(50–64 years) patients with AF on anticoagulation;
however, this was not statistically significant (OR:
0.45, 95% CI: 0.19–1.04, P=0.063). On the other
hand, elderly patients (65-74 years) with AF on
chronic anticoagulation had a lower incidence of
AMsI compared with those not on anticoagulation
(OR: 0.41, 95% CI: 0.24–0.70, P=0.001). Of the
patients diagnosed with AMsI, those with AF but
not on anticoagulation had more adverse outcomes
(both primary and secondary outcomes) compared to

RESULTS

Original Research
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Table 1. Baseline Demographics, Comorbidities, and Hospital Characteristics of Patients With Acute
Mesenteric Ischemia

Atrial fibrillation
(n=8,306)

No atrial fibrillation
(n=40,566)

77.45 (76.92–78.98)

62.74 (61.78–63.69)

5 (0.1)
114 (1.4)
2,662 (32.1)
5,526 (66.5)

3,762 (9.3)
4,764 (11.7)
18,898 (46.6)
13,142 (32.4)

Sex,* n (%)
Female
Male

5,170 (62.2)
3,136 (37.8)

24,800 (61.2)
15,722 (38.8)

Race, n (%)
White
Black
Hispanic
Asian or Pacific Islander
American Indian
Other/missing

5,305 (63.9)
370 (4.5)
310 (3.7)
100 (1.2)
68 (0.8)
2,153 (25.9)

22,596 (55.7)
2,796 (6.9)
2,436 (6.0)
780 (1.9)
248 (0.6)
11,033 (27.2)

267 (3.2)

3,703 (9.1)

Median income by patient ZIP code, n (%)
$1–$38,999
$39,000–$47,999
$48,000–$62,999
$63,000+
Missing

1,839 (22.6)
1,987 (23.9)
2,152 (25.9)
2,158 (26.0)
170 (2.0)

9,829 (24.2)
9,994 (24.6)
10,116 (24.9)
9,568 (23.6)
1,059 (2.6)

Payer, n (%)
Medicare
Medicaid
Private insurance
Self-pay
Other/missing

6,907 (83.2)
189 (2.3)
1,072 (12.9)
74 (0.9)
64 (0.8)

22,555 (55.6)
3,257 (8.0)
11,904 (29.3)
1,494 (3.7)
1,356 (3.4)

Admission type, n (%)
Emergency
Urgent
Elective
Other/missing

5,681 (68.4)
1,062 (12.8)
699 (8.4)
864 (10.4)

26,344 (64.9)
5,714 (14.1)
3,929 (9.7)
4,579 (11.3)

Comorbidities, n (%)
Hypertension
Hyperlipidemia
Heart failure
Chronic lung disease
Diabetes mellitus with complications
Liver disorders
Neurological disorders
Obesity
Peripheral vascular disease
Renal failure
Metastatic cancer
Valvular heart disease

4,345 (52.3)
996 (12.0)
2,881 (34.7)
2,572 (31.0)
325 (3.9)
185 (2.2)
621 (7.5)
335 (4.0)
1,227 (14.8)
1,720 (20.7)
178 (2.1)
1,141 (13.7)

19,340 (47.7)
5,289 (13.0)
4,097 (10.1)
7,969 (19.6)
1,305 (3.2)
1,562 (3.9)
2,418 (6.0)
2,073 (5.1)
4,353 (10.7)
4,510 (11.1)
1,347 (3.3)
1,969 (4.9)

Mean age, years (95% confidence interval)
Age group, n (%)
<35 years
35–49 years
50–74 years
75+ years

Smoking, n (%)

P
<0.001
<0.001

0.45

<0.001

<0.001
0.16

<0.001

0.08

0.001
0.25
<0.001
<0.001
0.18
0.004
0.03
0.06
<0.001
<0.001
0.02
<0.001

*There were nine observations for the sex category missing from the group without atrial fibrillation (weighted number: 44).
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those with AF who were on anticoagulation (Table
4). Patients with AF who were not on anticoagulation
were more likely to have small bowel resections
(25% vs 16%, P=0.03) and colectomy (25% vs 11%,
P<0.001). There were significantly greater numbers
of cases of shock and those requiring total parenteral
nutrition and intubation/mechanical ventilation
(all acting as surrogate markers of severity) in
groups not on anticoagulation compared to those
on anticoagulation. Furthermore, hospital charges,
length of stay, in-hospital mortality and nonroutine
discharges also were greater in the group not on
anticoagulation. The unadjusted odds of in-hospital
death in those with AMsI with AF who were not on
anticoagulation versus those with AMsI with AF who
were on anticoagulation was 2.09 with a 95% CI of
1.37–3.20 (P=0.006). After multivariate analysis,
however, this difference in mortality between the two
groups became statistically nonsignificant (OR: 1.85,
95% CI: 0.86–3.98, P=0.12).

DISCUSSION

The main findings of this study in a large number
of patients hospitalized with AMsI are that: 1) this
complication is more often present in patients with
AF than those without, and 2) patients with AF are
more likely to have worse outcomes, including higher

Table 2. Significant Predictors for Acute
Mesenteric Ischemia

Covariates
Atrial fibrillation
Age category
<35 years (reference)*
35–49 years
50–74 years
≥75 years
Sex: female vs male
Race: white vs black
Admission type:
emergency vs urgent
Hyperlipidemia
Use of anticoagulation
Tobacco use
Chronic blood loss anemia
Heart failure
Diabetes mellitus
Hypertension
Liver disorder
Neurological disorder
Obesity
Peripheral vascular disease
Renal failure
Valvular heart disease

Odds
ratio
1.16

95% CI
1.08–1.25

P
<0.001

–
2.24
4.55
4.39
1.35
1.73
1.64

–
1.90–2.65
3.88–5.34
3.72–5.17
1.27–1.43
1.53–1.96
1.42–1.89

–
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

0.69
0.70
0.77
1.80
1.31
0.74
0.93
1.39
0.73
0.76
2.11
1.10
1.24

0.63–0.75
0.59–0.83
0.69–0.86
1.59–2.05
1.21–1.41
0.69–0.79
0.87–0.99
1.21–1.59
0.66–0.81
0.66–0.86
1.93–2.31
1.01–1.19
1.13–1.37

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.04
<0.001
<0.001
<0.001
<0.001
0.03
<0.001

*Reference group = all other age groups were compared
to this age group.
CI, confidence interval.

Table 3. Adverse Outcomes in Acute Mesenteric Ischemia: With AF vs Without AF
Acute mesenteric
ischemia with AF
(n=8,306)

Acute mesenteric
ischemia without AF
(n=40,566)

Small bowel resection, n (%)

1,992 (24)

9,035 (22)

0.14

Colectomy, n (%)

1,955 (24)

7,128 (18)

<0.001

Shock, n (%)

1,418 (17)

5,157 (13)

<0.001

Total parenteral nutrition, n (%)

1,430 (17)

4,346 (11)

<0.001

8,287 (20)
87,114
(80,840–93,388)
6,870* (21)

<0.001
<0.001

2,946 (35.5)

7,756 (19)

<0.001

6,553 (79)

20,842 (51)

<0.001

Outcomes

Intubation and/or mechanical ventilation, n (%)
Mean hospital charges in U.S. dollars, n (95% CI)
Length of stay > 14 days (>75% quartile), n (%)
In-hospital mortality, n (%)
Nonroutine discharges, n (%)

2,701 (33)
110,802
(101,378–120,226)
1,884* (35)

P

<0.001

*Patients who died prior to discharge were excluded.
AF, atrial fibrillation; CI, confidence interval.
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Table 4. Adverse Outcomes in Acute Mesenteric Ischemia: AF on Anticoagulation vs AF Not on Anticoagulation
Outcomes

AF on anticoagulation
(n=680)

AF no anticoagulation
(n=7,626)

P

111 (16)
76 (11)

1,881 (25)
1,880 (25)

0.03
<0.001

68.41 (10)
27 (4)

1,350 (18)
1,403 (18)

0.02
<0.001

68 (10)

2,633 (35)

<0.001

42,426
(34,701–50,150)

116,931
(106,854–127,009)

<0.001

43* (6)

1,068* (14)

<0.001

148 (22)
378 (56)

2,798 (37)
6,175 (81)

<0.001
<0.001

Small bowel resection, n (%)
Colectomy, n (%)
Shock, n (%)
Total parenteral nutrition, n (%)
Intubation and/or mechanical ventilation, n (%)
Mean hospital charges in U.S. dollars,
n (95% CI)
Length of stay > 14 days (>75% quartile), n (%)
In-hospital mortality, n (%)
Nonroutine discharges, n (%)
*Patients who died prior to discharge were excluded.
AF, atrial fibrillation; CI, confidence interval.

in-hospital mortality and greater likelihood of small
bowel resection, colectomy and shock. Moreover, elderly
patients with AF who were on anticoagulation were
less likely to be admitted with AMsI than those not on
anticoagulation, and patients with AF on anticoagulation
had fewer complications, including hemodynamic
compromise with shock, small bowel resection,
colectomy and need for intubation or mechanical
ventilation. Length of stay and hospital charges also
were significantly less in the anticoagulation group.
AMsI is a serious medical condition with high
mortality and morbidity.6 Therefore, it is necessary
to define factors affecting poor outcomes in order
to reduce complications associated with AMsI and
improve health outcomes. Due to its low incidence,
knowledge about reported outcomes and mortality
predictors has been obtained from retrospective
studies involving a limited number of patients.
Although AF is a known risk factor due to the potential
for thromboembolism, the incidence of AMsI as a
complication and the impact of anticoagulation in
patients with AF on outcomes have not been fully
defined. Our study, which used a national database
comprised of a large number of patients, helps fill
some of these knowledge gaps.
AMsI results from perfusion impairment mainly due
to vascular occlusion (arterial thrombus/embolus
or venous thrombus) or nonocclusive low-flow
state (vasospasm or decreased cardiac output) with
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decreased perfusion to the small bowel and colon.20
Since AMsI results from circulatory insufficiency
in the mesenteric arteries, it is logical to expect that
most of the risk factors would be vascular in nature.
In our study, age 65–74 years, peripheral vascular
disease, chronic blood loss anemia, liver disorders
and valvular heart disease were all associated with
increased risk of AMsI.
Advanced age is a known risk factor for vascular
disease and mesenteric ischemia. The presence
of peripheral arterial disease, which reflects
overall atherosclerotic burden21 and is therefore a
surrogate for mesenteric atherosclerosis, also was
predictive of AMsI regardless of the presence of AF.
Valvular heart diseases increase the risk for AF and
thromboembolism, and thereby for AMsI.22,23 Chronic
blood loss anemia also was associated with increased
risk for AMsI. Although the precise mechanism
behind this is not clear, a secondary hypercoagulable
state due to thrombocytosis associated with iron
deficiency, microcytosis or reduction in red blood
cell deformability24-26 could be responsible, especially
when combined with the diminished oxygen-carrying
capacity of reduced hemoglobin levels precipitating
hypoxia in hypoperfused areas with preexisting
atherosclerotic disease.27 This could be further
exaggerated by hemodynamic stress imposed by
cardiac arrhythmias, such as AF, which by itself is
associated with increased risk of thromboembolism.28
This may explain the 127% greater risk for AMsI

Original Research

among patients with AF (0.25%) when compared to
non-AF patients (0.11%).
Another important finding of our study is the
reduced risk of AMsI in patients with diabetes,
hyperlipidemia, hypertension, tobacco use or obesity.
This is in contrast to the greater risk of ischemic
stroke/transient ischemic attack in patients with AF
with a history of hypertension and diabetes. The
reason for this discrepancy is not known but could
be related to the previously described paradoxical
effect of hyperlipidemia or obesity as protective
against mortality in high-risk patients (i.e. those
with advanced heart diseases such as myocardial
infarction, heart failure, AF, etc.)29-34 This paradoxical
effect has been attributed to better care received by
patients with risk factors or coronary artery disease, as
they are more likely to receive beta blockers, statins,
angiotensin-converting enzyme (ACE) inhibitors
or antiplatelet agents, which improve survival and
thus contribute to the paradoxically lower risk of
cardiovascular events. A subanalysis of patients on
cardioprotective medications (beta blocker, ACE
inhibitor, antiplatelet) would be interesting. However,
information regarding these medications cannot be
obtained using the NIS database due to the lack of
associated ICD codes.
The overall prognosis of patients with AMsI is poor,
and our results indicate that patients with AF do
worse than those without AF. In-hospital mortality in
patients with AMsI was 22%, but in AF patients the
in-hospital mortality was 85% higher (35.5%) than
in non-AF patients (19.1%). The higher in-hospital
mortality in AF when compared with non-AF patients
could be partly explained by the older age of the
AMsI patients, a known risk factor for increased
mortality35,36 and higher prevalence of comorbidities.
About two-thirds of the patients in the AF group
were older than 75 years of age compared to only
one-third in the non-AF group. AF patients also were
more likely to have valvular heart disease (13.7% vs
4.8% in patients without AF), a known risk factor for
atrial enlargement and systemic embolization,22,23,37
coagulation disorder or liver disease. Previous studies
have shown that the time lapse between the onset of
symptoms and surgical intervention for AMsI, extent
of tissue damage,35 and presence of shock, acidosis,
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previous cardiac illness, acute renal failure and colon
involvement were predictors of higher in-hospital
mortality and perioperative death.38 Early diagnosis
of AMsI, especially before the onset of intestinal
necrosis and peritonitis, is critical to the patient’s
survival,35 with the survival rate decreasing from 50%
among patients diagnosed less than 24 hours after the
onset of symptoms to 30% among those diagnosed
more than 24 hours after onset of symptoms.39
Complications of AMsI, such as ileus, peritonitis,
pancreatitis and gastrointestinal bleed, may mask
AMsI symptoms, delay diagnosis and contribute to
higher mortality.35,40 In our study, more AF than nonAF patients had emergency admissions and were
sicker, with greater incidence of shock and intestinal
damage requiring colectomy, total parenteral nutrition,
intubation and mechanical ventilation; this prolonged
the hospital stay and resulted in significantly higher
hospital charges and in-hospital mortality (Table 3).
This might be related to the sudden embolic occlusion
of the mesenteric artery in AF, without time for the
bowel to develop sufficient collaterals or activate
compensatory responses, contributing to graver
outcomes resulting from bowel infarction, systemic
inflammatory response syndrome, sepsis, respiratory
failure (intubation/mechanical ventilation), multiple
organ dysfunction and death.41
In AF patients on chronic anticoagulation, these
complications were significantly reduced when
compared to AF patients not on anticoagulation
(Table 4), suggesting that patients with AF who
are not on anticoagulation are more likely to have
thromboembolic events, including AMsI, and
ultimately worse outcomes. This provides support
for the recommendation for chronic anticoagulation
for protection against AMsI, similar to what has been
endorsed to reduce risk of stroke in AF.3,12,42-44
Limitations
The main limitation of our study is that it is a
retrospective analysis of an administrative database
with the potential for selection bias in a hospitalized
population with mesenteric ischemia. The NIS
database, due to its administrative nature, largely
relies on ICD codes; thus, factors that do not have
an ICD code cannot be studied using this database.
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The patients were gravely ill and had complex
disease processes occurring that could have impacted
outcomes, including hemodynamic stress in sicker
patients that could have aggravated rhythm and rate
control. Information on such processes could not be
obtained. Multivariate analysis was performed to
account for known baseline differences; however, the
impact of undocumented confounding factors could not
be completely dissected in this retrospective analysis.
The type of AF (persistent vs paroxysmal) could have
had an impact on patient outcomes. However, this
effect could not be studied using this administrative
database as the types of AF cannot be differentiated
using ICD codes. Prior studies suggest that
thromboembolic outcomes do not differ based on the
type of AF.45,46 The individual risk of thromboembolism
based on an individual’s CHADS2VASc score and
the resultant outcomes in the same patient could
not be calculated using this administrative database.
Based on the current data, we do not know if the
patients with a high CHADS2VASc score were
anticoagulated, whether patients with AMsI had high
thromboembolic risk and were not anticoagulated for
other reasons, or whether patients were at low risk of
thromboembolism. Short of a randomized controlled
study, use of an institutional database with patientlevel information could help further clarify this
question. Despite these limitations, our study, one of
the largest assessing the relationship between AF and
AMsI, identifies important differences in outcomes
in patients with and without AF and provides data in
support of the protective role of anticoagulation in
reducing complications of AMsI.

CONCLUSIONS

In this largest cohort of patients with acute mesenteric
ischemia, patients with atrial fibrillation had
significantly higher in-hospital mortality and poorer
outcomes when compared to patients without AF.
Since AF is a common arrhythmia observed in the
community and after surgery, it is critical to manage
the risk of thromboembolism appropriately.2-4,44 Our
results emphasize the need for aggressive management
in this high-risk subgroup. Among patients with AF,
those who were not on anticoagulation had worse
outcomes than those on anticoagulation, and therefore
anticoagulation should be considered in patients with
thromboembolic risk factors.
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Patient-Friendly Recap
• Acute mesenteric ischemia results in restricted
blood flow to vital organs and can be deadly if
left untreated.
•A
 fter identifying which clinical factors increased
the risk for developing this syndrome, the authors
zeroed in on the finding that patients who also
had a history of the heart rhythm disorder atrial
fibrillation fared significantly worse.
• On further analysis, they discovered that patients
who had been taking anticoagulation medication
for their atrial fibrillation not only developed
mesenteric ischemia less often but that the ones
who did develop the syndrome experienced
fewer complications.
• Study results led the authors to encourage
anticoagulant use for atrial fibrillation and
other high-risk clotting conditions, especially
in patients aged 65–74 years, to prevent acute
mesenteric ischemia.
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